Panel Discussion: The Industry Perspective on Navigating the Evolving Global Regulatory CMC Landscape for Targeted Radiopharmaceuticals

8:20 am - Wednesday 2nd December 2026

  • Understanding how evolving global regulatory expectations across manufacturing, comparability, isotope supply and control strategy are reshaping the development and commercialisation pathway for targeted radiopharmaceuticals
  • Exploring where regulatory fragmentation continues to create challenges across multinational TRP programs and determining how industry leaders are building more globally aligned CMC strategies to reduce downstream delays
  • Examining how leading developers are proactively approaching scalability, manufacturing readiness, and supply resilience earlier in development to strengthen long-term regulatory and commercial success

Speakers:

Director - Regulatory Chemistry Manufacturing & Controls & MedTech
Telix Pharmaceuticals
Director - Chemistry, Manufacturing, Controls, Regulatory Affairs & Radiopharmaceuticals
AstraZeneca
Vice-President, Head of Regulatory Affairs
Bayer